The Validation Institute Names USI as a 2019 Health Value Award Finalist

Currently in its second year, the Validation Institute’s Health Value Awards program is designed to recognize outstanding services, products and programs across 34 categories spanning the healthcare industry. USI was recently recognized as one of 85 Health Value Award finalists for 2019, for its delivery of innovative Reference Based Reimbursement solutions and services to healthcare…

USI’s 2019 Employee Benefits Outlook

The 2019 Employee Benefits Outlook offers expert insights from USI’s national practice leaders on the trends and market conditions affecting benefit programs. The Outlook provides thoughts and perspectives on trends, topical issues and solutions for consideration, including: How artificial intelligence is increasing the efficiency and effectiveness of HR teams Improving price transparency to manage pharmaceutical costs…

Reference-Based Pricing — A “Transparent” Way of Paying Health Care Providers

By Manoj Rajwani, USI Vice President, Employee Benefits Employers and their employees continue to struggle with skyrocketing health care costs.  The job market is already competitive, and many companies are overwhelmed with  how to manage the benefit costs but still offer a quality program at the same time.  Many of those same organizations are diligent…

NJ Passes New Balance Billing Law

On June 1, 2018, NJ Gov. Murphy passed the Out-of-Network Consumer Protection, Transparency, Cost Containment and Accountability Act. This bill applies to emergency services and other care provided by out-of-network physicians in in-network settings (i.e. hospital-based physicians). It takes effect on September 1, 2018. The new law provides reforms to several aspects of the state’s…

Stepping into Lower Drug Costs

Step therapy can save money but some say there can be a downside. One way to keep your health benefit plan’s overall costs lower is to encourage employees to choose generic drugs whenever possible. The U. S. healthcare system saved $1.68 trillion from 2005 to 2014 by using generic drugs, according to the IMS Institute…